NCT04801342: Neurocognitive Outcome of Bilateral or Unilateral Hippocampal Avoidance WBRT With Memantine for Brain Metastases

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation therapy, Other

Key Eligibility Criteria:

Gender: All
Age: 20 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with prior radiation therapy, unless it was for 5 intracranial metastatic lesion(s) or less; Patients with evidence of diffuse leptomeningeal metastasis

Comments are closed.

Up ↑